Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 627

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 3
Chunk 627
---
8.06  
     103,608 
  
    Equity compensation plans not approved by security holders 
     —  
     —  
     — 

(1)
Represents stock options outstanding under the 2021 Plan.

(2)
Our 2021 Plan has an evergreen provision that allows for an annual increase on each January 1 from January 1, 2025 and ending on and
including January 1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of our shares of common stock outstanding
on the final day of the immediately preceding calendar year or (B) such smaller number of shares as is determined by our Board of Directors.

Pay
Versus Performance Table

The
following table sets forth information concerning the compensation of our named executive officers, or NEOs, the compensation actually
paid to our NEOs, as determined under SEC rules (and described below), our total shareholder return and our net loss, in each case for
each of the fiscal years ended December 31, 2022, 2023 and 2024:

    (a) 
    (b)  
    (c)  
    (d)  
    (e)  
    (f)  
    (h) 
  
    Year 
    Summary Compensation Table Total for PEO ($)  
    Compensation Actually Paid to PEO ($)(1)  
    Average Summary Compensation Table Total for non-PEO NEOs ($)  
    Average Compensation Actually Paid to Non-PEO NEOs ($)(1)  
    Value of Initial Fixed $100 Investment Based on: Total Shareholder Return ($)  
    Net Loss ($) 
  
    2024 
    $1,157,217  
    $1,029,281  
    $949,640  
    $845,621  
    $48  
    $(15,022,027)
  
    2023 
    $1,001,249  
    $1,122,094  
    $744,039  
    $799,786  
    $121  
    $(15,423,471)
  
    2022 
    $1,680,532  
    $(38,385) 
    $1,062,955  
    $500,074  
    $41  
    $(14,322,798)